Research Paper On Dry Eye Disease
FDA approves new medication for dry eye disease
In the U.S roughly 16 million people are diagnosed with dry eye disease. (3)“Dry eye disease includes a group of conditions in which the eye does not produce an adequate volume of tears or when the tears are not of the correct consistency.‘ Dry eyes disease affects roughly five percent of the adult population age 30-40 and ten to fifteen percent of adults over the age of 65 [1]. If the disease is left untreated it can cause serious issues such as inflammation to the eye, ulcers or scares in the cornea, as well as serious pain. [2]
Shire, a biotechnology company finally got the approval for Xiidra (lifitegrast ophthalmic solution) from the U.S. Food and Drug Administration (FDA), after resubmitting
the new drugs application (4). “The approval of Xiidra marks a new day in treatment options for patients with dry eye disease, with the only prescription eye drop approved in the U.S. specifically to treat both the signs and symptoms of the condition,” said Flemming Ornskov, M.D., MPH, CEO, Shire (3)
Although the safety of the Xiidra for children under 17 is still unknown. Launching of the Xiidra in the U.S is hoped to be in the third quarter of 2016. Excitement for the launch. The approval of this brings great excitement to those suffering with the dry eye disease.
In the U.S roughly 16 million people are diagnosed with dry eye disease. (3)“Dry eye disease includes a group of conditions in which the eye does not produce an adequate volume of tears or when the tears are not of the correct consistency.‘ Dry eyes disease affects roughly five percent of the adult population age 30-40 and ten to fifteen percent of adults over the age of 65 [1]. If the disease is left untreated it can cause serious issues such as inflammation to the eye, ulcers or scares in the cornea, as well as serious pain. [2]
Shire, a biotechnology company finally got the approval for Xiidra (lifitegrast ophthalmic solution) from the U.S. Food and Drug Administration (FDA), after resubmitting
the new drugs application (4). “The approval of Xiidra marks a new day in treatment options for patients with dry eye disease, with the only prescription eye drop approved in the U.S. specifically to treat both the signs and symptoms of the condition,” said Flemming Ornskov, M.D., MPH, CEO, Shire (3)
Although the safety of the Xiidra for children under 17 is still unknown. Launching of the Xiidra in the U.S is hoped to be in the third quarter of 2016. Excitement for the launch. The approval of this brings great excitement to those suffering with the dry eye disease.